Testing effectiveness (Phase 2)Looking for participantsNCT06149481
What this trial is testing
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Who this might be right for
Metastatic Colorectal Cancer
National Cancer Institute (NCI) 60